Zika virus disease 

Zika virus disease

at a glance

Zika virus is a mosquito-borne flavivirus. The virus is transmitted through the bite of an infected Aedes mosquito, mainly Aedes aegypti, in tropical and subtropical regions. The same mosquito also transmits the viruses causing dengue, chikungunya and yellow fever. Zika virus is also transmitted from mother to fetus during pregnancy, through sexual contact, transfusion of blood and blood products, and organ transplantation. The incubation period (the time from exposure to symptoms) of Zika virus disease is estimated to be 3–14 days. Symptoms are similar to other arbovirus infections, and include fever, skin rashes, conjunctivitis, muscle and joint pain, malaise, and headache. These symptoms are usually mild and last for 2-7 days and often do not require any specific treatment. However, Zika virus infection during pregnancy is a cause of microcephaly and other congenital abnormalities in the developing fetus and newborn and can lead to pregnancy complications such as fetal loss, stillbirth, and preterm birth. Zika virus was shown to be a trigger of the Guillain-Barré syndrome neuropathy and myelitis, particularly in adults and older children. Zika virus infection can only be confirmed by laboratory tests of blood or other body fluids, such as urine or semen.

infants with

Zika-associated defects


Zika virus in pregnancy

countries reported mosquito-transmitted Zika infection


in 2019

People infected 

develop symptoms

1 in 5

in 2019

of the world's population is at risk

2.7 Billion

living in at risk areas 

Zika virus was first identified in April 1947 in rhesus monkeys in the  Zika forest, Uganda. The first recorded outbreak of Zika virus disease was reported from Micronesia in 2007, followed by a large outbreak of Zika virus infection in French Polynesia and other countries and territories in the Pacific in 2013. In 2015, Brazil reported a large outbreak of Zika virus infection, found to be associated with Guillain-Barré syndrome and microcephaly.  To date, a total of 86 countries and territories have reported evidence of mosquito transmitted Zika infection. 

Currently, there is no therapy available to treat of prevent Zika virus infection or its associated diseases. Protection against mosquito bites remains as a key preventive measure.

Zika virus disease Vaccines


Pre-clinical proof of concept

Clinical proof of concept

    Phase Ia    

    Phase Ib    

    Phase IIa    


     Phase IIb     

    Phase III     

Join European Vaccine Initiative mailing list for updates on projects, training and funding opportunities

© 2020 European Vaccine Initiative. Designed by European Vaccine Initiative